

Supplementary Materials for
Nutrients and pheromones promote insulin release to inhibit courtship drive

Liwei Zhang*, Xuan Guo, Wei Zhang*

*Corresponding author. Email: wei_zhang@mail.tsinghua.edu.cn (W.Z.); lwzhang@cau.edu.cn (L.Z.)

Published 9 March 2022, *Sci. Adv.* **8**, eabl6121 (2022)
DOI: 10.1126/sciadv.abl6121

This PDF file includes:

Figs. S1 to S8
Table S1

Supplementary figures and table

Fig. S1




Fig. S1. Screening for neurotransmitter genes involved in inter-male courtship. (A and B) *ilp2¹* mutant males exhibited increased courtship activity towards *D. mojavensis* virgin females. Courtship index and single-wing extension number were quantified in CS and *ilp2¹* mutant males. N=6-7 for each genotype. Mann-Whitney nonparametric test was used. **p < 0.01, *p < 0.05. Data were represented as mean ± SEM. (C and D) No inter-male courtship was observed in the mutants of neurotransmitter or receptor genes except for the *Trh^{GKO}* mutant males. Knocking down serotonin receptors in IPCs displayed no inter-male courtship. Courtship index (A) and single-wing extension

number (B) between males with indicated genotypes. N=4-7 in each group. One-way ANOVA followed with Dunnett test for multiple comparisons was used and statistical differences were represented as following: **p < 0.01, ****p < 0.0001. Data were represented as mean ± SEM.

Fig. S2




Fig. S2. Knockdown CCAP or silencing CCAP/PPK23 co-labeled neurons didn't affect male-female courtship. (A to C) Courtship activity between pairs of indicated males and *w¹¹¹⁸* virgin female. None of silencing CCAP/PPK23 neurons in (A), suppressing CCAP expression by PPK23-Gal4 in (B) or suppressing *ppk23* expression by CCAP-Gal4 in (C) disrupted male-female courtship.

N =11-12 in each group of (A), n=12-14 in each group of (B) and n=6-10 in each group of (C). Mann-Whitney nonparametric tests were used. Data were represented as mean \pm SEM. (D and E) Courtship index and single-wing extension number in indicated groups. One-way ANOVA nonparametric Kruskal-Wallis tests followed with Dunn's test compared with U-Dcr2; U-CCAP-RNAi group were used. Data were represented as mean \pm SEM. N=7-12 in each group. *p < 0.05, ***p < 0.001. (F) Single-wing extension numbers in indicated groups when InR signaling in P1 neurons were disrupted. N=7-12 in each group. One-way ANOVA nonparametric Kruskal-Wallis tests followed with Dunn's test compared with R71G01-Gal4 were used. Data were represented as mean \pm SEM. *p < 0.05, **p < 0.01, ****p < 0.0001. (G) Single-wing extension numbers in indicated groups when ppk23/CCAP neurons were silenced. N=7-11 in each group. One-way ANOVA nonparametric Kruskal-Wallis tests followed with Dunn's test compared with Fru-LexA was used. Data were represented as mean \pm SEM. *p < 0.05, **p < 0.001.

Fig. S3




Fig. S3. Quantification of ILP2 release in IPCs. (A) Mean fluorescence intensities in IPCs stained with ILP2 and RFP antibodies respectively. In two adjacent groups, A.U. values between anti-ILP2 and anti-RFP were compared. Males (*ilp2-LexA/+; lexAop-mCD2-RFP/+*) were grouped with conspecific female and male, as well as mock control. Mann-Whitney nonparametric tests were used in each treatment. Data were represented as mean \pm SEM. **** $p < 0.0001$. (B) A.U. value ratios (anti-ILP2 divided by anti-RFP) were quantified between genotypes in (A). One-way ANOVA nonparametric Kruskal-Wallis tests followed with Dunn's test compared with mock group were used. Data were represented as mean \pm SEM. **** $p < 0.0001$. (C-E) More image samples from three groups in (A). Bar: 20 μ m.

Fig. S4




Fig. S4. Image samples of ILP2 immunostainings in various manipulations. (A to D) IPCs immunostaining intensities after optogenetic activation of ppk23+ cells (A and B), coupled with CCAP-RNAi in ppk23+ cells (C) or coupled with CCAP-R-RNAi in IPCs (D). Bar: 20µm.

Fig. S5




Fig. S5. Quantification of ILP2 level under optogenetic manipulations. (A) Mean fluorescence intensity (A.U.) of ILP2 and RFP when supplied with all-trans retinal (+ATR) or not (-ATR) in males (UAS-CsChrimson/ilp2-lexA; LexAop-mCD2-RFP/ppk23-gal4). Related to Fig. 5G. The diminishment of RFP intensity in +ATR treatment might be from either accompanying release with DILPs or reduced transcript level of RFP during the long-term activation of IPCs. (B) Normalization (ratio) of ILP2 immuno-intensity with respect to RFP level with all-trans retinal (+ATR) or not (-

ATR) in males (UAS-CsChrimson/ilp2-lex; LexAop-RFP/ppk23-gal4) related to (A). (C and D)
More image samples from two groups in (A). Bar: 20µm.

Fig. S6




Fig. S6. Dense core vesicles localizations in ppk23+/CCAP+ cells axon and expression of CCAP-R on IPCs. (A) Visualization of dense core vesicles in M-cells' (vGlut-Gal80; ppk23-Gal4) axonal projections in the VNC. Anti-GFP signals were observed in males of ppk23-Gal4>UAS-preproANF-Emerald. No staining signal was observed outside the VNC, indicating that neuropeptides were released within the VNC. Bar: 20µm. (B) Visualization of axonal projections of M-cells (vGlut-Gal80; ppk23-Gal4) in the VNC. Anti-GFP signals were observed in males of ppk23-Gal4>UAS-mCD8-GFP. White arrow indicated the fiber bundles that enter the VNC from leg ppk23+ neurons. Bar: 20 µm. (C) No dense core vesicles signal was found on male legs (vGlut-Gal80; ppk23-Gal4>UAS-preproANF-Emerald). Bar: 20 µm. (D) ppk23+ neurons were found on male legs with GFP (vGlut-Gal80; ppk23-Gal4>UAS-mCD8-GFP). Bar: 20 µm. (E) Co-localization between CCAP-R+ neurons (R64B05-Gal4>GFP) and IPCs (anti-ILP2). Bar: 20 µm.

Fig. S7




Fig. S7. Effects of sugar meal on courtship in fasted males. (A and B) Courtship and single-wing extension number in CS, *ilp2¹* heterozygous and *ilp2¹* homozygous mutant males toward *w¹¹¹⁸* virgin females. All males were starved for 16 hours during which water was supplied, and then fed with 100 mM fructose for 3 min before test. Mann-Whitney nonparametric test was used in two groups of the same genotypes. **p* < 0.05, ****p* < 0.001. Data were represented as mean ± SEM. (C) Mean fluorescence intensity (A.U.) of ILP2 and RFP in fasted, fructose- or glucose-fed males related to Fig. 3A-B. (D) Normalization (ratio) of ILP2 immuno-intensity with respect to RFP level in fasted, fructose- or glucose-fed males related to (C). One-way ANOVA nonparametric Kruskal-Wallis tests followed with Dunn's test compared with fasted group were used. Data were represented as mean ± SEM. ***p* < 0.01, ****p* < 0.001. (E to G) Representative samples from three groups in (C). Bar: 20 μm.

Fig. S8




Fig. S8. Putative connections between IPCs and P1 neurons and CCAP expression in M-cells. (A) GRASP signals were detected between IPCs and P1 neurons. Genotype: *ilp2-LexA/+*; UAS-

CD4-spGFP1-10, LexAop-CD4-spGFP11/R71G01-Gal4. Dotted circles indicated the GRASP signals. Bar: 20 μ m. **(B)** Spatial relation between IPCs and P1 neurons. Genotype: *ilp2-LexA/UAS-tdTomato*; *LexAop-mCD8-GFP/R71G01-Gal4*. Dotted circles indicated the adjacent regions where IPCs and P1 neurons are in close proximity. Bar: 20 μ m. **(C)** Q-PCR quantification of leg tarsal CCAP transcripts. Top gel image was correlated with column below. *UAS-CCAP-RNAi* males were used as control and *vGlut-Gal80*; *ppk23-Gal4>UAS-CCAP-RNAi* males were treatment group. Mann-Whitney nonparametric test was used for statistical analysis. N=3 for each group. **p* < 0.05. Data were represented as mean \pm SEM.

Table. S1. RNAi lines and mutant alleles used in screening.

| Lines used in Figure 3. | | Lines used in Figure S1. | |
|---------------------------------------|--------|--|--------|
| Gene/Allele | BDSC # | Gene/Allele | BDSC # |
| Dromyosuppressin R | 25832 | <i>GluRIA^{attP}</i> | 84506 |
| <i>Fmrf</i> R | 25858 | <i>Oamb^{del}</i> | 84707 |
| Diuretic hormone 31 R1 | 25925 | <i>Dop1R2^{KO}</i> | 84719 |
| Allatostatin R2 | 25935 | <i>Dop2R^{KO}</i> | 84720 |
| Leucokinin R | 25936 | <i>DopEcR^{KOGal4}</i> | 84717 |
| NPF R | 25939 | <i>SerT^{attP}</i> | 84572 |
| Capa R | 27275 | <i>Trh^{GKO}</i> | 86146 |
| Allatostatin R | 27280 | <i>Trh⁰¹</i> | 86147 |
| CCK like R | 27494 | <i>Trh^{e01440}</i> | 10531 |
| CCHamide-1 R | 27669 | <i>UAS-5-HT1A-IR^{JF01852}</i> | 25834 |
| Allatostatin C R1 | 27506 | <i>UAS-5-HT2A-IR^{JF02157}</i> | 31882 |
| short NPF R | 27507 | <i>UAS-5-HT1B-IR^{JF01851}</i> | 25833 |
| Fsh-Tsh-Like R | 27509 | | |
| Tachykinin-like R at 99D | 27513 | | |
| Dromyosuppressin R1 | 27529 | | |
| Pyrokinin 1 R | 27539 | | |
| Eclosion hormone R | 38346 | | |
| Diuretic hormone 44 R1 | 28780 | | |
| Pyrokinin 2 R2 | 28781 | | |
| ETH R | 28783 | | |
| Proctolin R | 29414 | | |
| AKH R | 29577 | | |
| Pyrokinin 2 R1 | 29624 | | |
| Cardioacceleratory peptide R (CCAP R) | 31490 | | |
| SIFamide R | 34947 | | |

| | | | |
|--------------------------|-------|--|--|
| Tachykinin like R at 86C | 31884 | | |
| Bursicon R | 31958 | | |
| Pdf R | 38347 | | |